Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Illumina, Adaptive Biotechnologies, Personalis, More

Illumina NovaSeq 6000 v1.5 Reagent Kit

Illumina has launched a new NovaSeq 6000 reagent kit that the company said could reduce sequencing costs for a human genome to $600.

The v1.5 kit offers improved quality, with an average Q30 score above 85 percent for read lengths up to 2x150 bp. Additional cycles per kit enables full support for unique molecular identifiers. The kits also double shelf life — up to six months — and are compatible with the new Illumina DNA PCR-Free Prep kit.


Adaptive Biotechnologies ImmunoSeq T-Map COVID Service

Adaptive Biotechnologies has launched the immunoSeq T-Map COVID, a proprietary research product and data-analysis service to measure the T cell immune response to vaccines in development and track the persistence of that response over time.

The product leverages data from more than 1,000 patients to provide researchers with a quantitative map of T cell receptors and SARS-CoV-2 antigens that elicit an immune response. These data will be available through Adaptive's cloud-based immunoSeq Analyzer and is powered by ImmuneCode, an open database developed in partnership with Microsoft.


Personalis NeXT Liquid Biopsy

Personalis has launched NeXT Liquid Biopsy, an exome-scale blood-based tumor-profiling assay for advanced-stage solid tumor cancer patients. According to the company, the test monitors over 20 times more genes than most targeted liquid biopsy panels on the market. Personalis believes its more comprehensive option can help biopharmaceutical companies advance their understanding of tumor biology, including resistance mechanisms, to aid in the development of next-generation cancer therapies.


For more new products and services, please visit the New Products page on our website.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.